ImmunoCellular is a L.A.-based clinical stage company developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular's pipeline includes:
- a Stem-to-T-cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells;
- ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma;
- ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer.
- ImmunoCellular recently suspended further patient randomization in its phase 3 trial of ICT-107 in HLA-A2 patients while it pursues a collaborative arrangement or acquisition of its ICT-107 program.